National Comprehensive Cancer Network Announces Research Funding For Biomarker-Directed Therapy In Metastatic Colorectal Cancer, In Collaboration With Fight CRC And Pfizer
Portfolio Pulse from Benzinga Newsdesk
The National Comprehensive Cancer Network (NCCN) has announced research funding for biomarker-directed therapy in metastatic colorectal cancer. This initiative is in collaboration with Fight CRC and Pfizer Inc. (PFE).
August 09, 2023 | 1:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pfizer Inc. is collaborating with NCCN and Fight CRC on research funding for biomarker-directed therapy in metastatic colorectal cancer. This could potentially lead to advancements in Pfizer's cancer treatment portfolio.
The collaboration with NCCN and Fight CRC for research funding indicates Pfizer's active role in advancing cancer treatment. This could potentially enhance Pfizer's reputation in the field, attract more partnerships, and ultimately, boost its stock price in the short term.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80